NOVAST Laboratories, Limited (SHE:301569)
China · Delayed Price · Currency is CNY 18.22
+0.44 (2.47%)
Oct 30, 2026, 3:04 PM CST
NOVAST Laboratories Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,010 | 895.47 | 866.22 | 700.43 | 550.07 | 646.38 |
Other Revenue | - | - | - | - | - | 0 |
| 1,010 | 895.47 | 866.22 | 700.43 | 550.07 | 646.38 | |
Revenue Growth | - | 3.38% | 23.67% | 27.33% | -14.90% | 14.34% |
Cost of Revenue | 421.23 | 416.29 | 411.35 | 369.14 | 280.7 | 335.15 |
Gross Profit | 588.55 | 479.18 | 454.87 | 331.29 | 269.37 | 311.23 |
Selling, General & Admin | 130 | 127.07 | 112.98 | 152.55 | 131.89 | 115.42 |
Research & Development | 93.15 | 100.97 | 101.73 | 88.74 | 102.5 | 82.01 |
Other Operating Expenses | 10.48 | 4.83 | 2.64 | 2.3 | 2.18 | 0.47 |
Operating Expenses | 235.21 | 234.44 | 216.48 | 244.63 | 231.35 | 202.72 |
Operating Income | 353.34 | 244.74 | 238.39 | 86.66 | 38.03 | 108.51 |
Interest Expense | - | - | - | - | - | -3.8 |
Interest & Investment Income | 35.21 | 36.1 | 35.6 | 28.14 | 11.09 | 4.54 |
Currency Exchange Gain (Loss) | -20.04 | -20.04 | 12.59 | 9.05 | 40.37 | - |
Other Non Operating Income (Expenses) | -32.65 | -0.09 | -0.06 | -0.02 | 0.44 | -0.05 |
EBT Excluding Unusual Items | 335.87 | 260.71 | 286.52 | 123.83 | 89.93 | 109.2 |
Gain (Loss) on Sale of Investments | -0.24 | 0.01 | 0.18 | 0.4 | 1.09 | -0.97 |
Gain (Loss) on Sale of Assets | - | - | - | - | 32.58 | - |
Asset Writedown | 17.44 | -0.14 | -0.16 | -1.53 | - | -0.67 |
Other Unusual Items | 2.56 | 2.56 | 3.53 | 13.44 | 6.61 | 0.26 |
Pretax Income | 355.63 | 263.13 | 290.08 | 136.13 | 130.21 | 107.82 |
Income Tax Expense | 44.41 | 35.31 | 29.93 | 20.34 | 17.21 | 18.21 |
Net Income | 311.22 | 227.82 | 260.15 | 115.79 | 113 | 89.61 |
Net Income to Common | 311.22 | 227.82 | 260.15 | 115.79 | 113 | 89.61 |
Net Income Growth | - | -12.43% | 124.67% | 2.47% | 26.11% | -22.68% |
Shares Outstanding (Basic) | 759 | 758 | 758 | 758 | 753 | 597 |
Shares Outstanding (Diluted) | 759 | 758 | 758 | 758 | 753 | 597 |
Shares Change | - | - | - | 0.60% | 26.11% | 3.10% |
EPS (Basic) | 0.41 | 0.30 | 0.34 | 0.15 | 0.15 | 0.15 |
EPS (Diluted) | 0.41 | 0.30 | 0.34 | 0.15 | 0.15 | 0.15 |
EPS Growth | - | -11.77% | 126.67% | -0.00% | 0% | -25.00% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 316.55 | 247.28 | 161.16 | 73.96 | 139.42 | 130.4 |
Free Cash Flow Per Share | 0.42 | 0.33 | 0.21 | 0.10 | 0.18 | 0.22 |
Dividend Per Share | - | - | 0.090 | - | - | - |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 58.28% | 53.51% | 52.51% | 47.30% | 48.97% | 48.15% |
Operating Margin | 34.99% | 27.33% | 27.52% | 12.37% | 6.91% | 16.79% |
Profit Margin | 30.82% | 25.44% | 30.03% | 16.53% | 20.54% | 13.86% |
Free Cash Flow Margin | 31.35% | 27.62% | 18.61% | 10.56% | 25.35% | 20.17% |
EBITDA | 392.12 | 280.07 | 272.53 | 120.73 | 70.7 | 140.74 |
EBITDA Margin | 38.83% | 31.28% | 31.46% | 17.24% | 12.85% | 21.77% |
D&A For EBITDA | 38.77 | 35.34 | 34.14 | 34.07 | 32.68 | 32.23 |
EBIT | 353.34 | 244.74 | 238.39 | 86.66 | 38.03 | 108.51 |
EBIT Margin | 34.99% | 27.33% | 27.52% | 12.37% | 6.91% | 16.79% |
Effective Tax Rate | 12.49% | 13.42% | 10.32% | 14.94% | 13.22% | 16.89% |
Advertising Expenses | - | 5.51 | 20.39 | 11.27 | - | - |